QuidelOrtho preliminary Q3 revenue $738-744M; beats on early respiratory demand

QuidelOrtho Corp

2023-Q3 EPS reported -$0.26 revenue$2,255,200,000

Total revenue $738-744M vs prior expectations; non-respiratory $557-560M, respiratory $181-184M.
Earlier-than-expected flu and COVID demand drove respiratory product sales higher in the quarter.
Full-year 2023 guidance maintained: rev $2.88-3.08B, adj EPS $4.85-5.30, adj EBITDA $800-830M.
All regions including China met or exceeded expectations; Q3 full results to be reported Nov 1, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

QuidelOrtho Corp reported fiscal third quarter ended October 1, 2023 results: revenue $738 million to $744 million. Guidance reaffirmed.

Period: fiscal third quarter ended October 1, 2023
Revenue: $738 million to $744 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu. Third Quarter 2023 Preliminary Unaudited Revenue Results • Total revenues of $738 million to $744 million; • Non-respiratory product revenue of $557 million to $560 million; and • Respiratory product revenue of $181 million to $184 million. “Our strong performance in

View on SEC.gov

Browse all earnings releases →

QuidelOrtho Corp filing history →

Source: SEC EDGAR

accession 0001906324-23-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.